Endometrial cancer treatment approved for NHS in England

8 February 2022

UK health technology assessor the National Institute for Health and Care Excellence (NICE) today issued a final appraisal determination (FAD) recommending the use of GlaxoSmithKline’s (LSE: GSK) Jemperli (dostarlimab) via the Cancer Drugs Fund (CDF) as a treatment option for patients with a common and aggressive form of advanced endometrial cancer (cancer of the womb lining).

The decision makes dostarlimab available via the CDF for adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer whose cancer has progressed on or following prior treatment with a platinum containing regimen (a type of chemotherapy). dMMR / MSI-H is a genetic deficiency that is thought to contribute to this cancer spreading particularly quickly making it difficult to treat with standard chemotherapy.

There are around 7,700 new cases of endometrial cancer each year in the UK, of which an estimated more than 170 women could be eligible for treatment with dostarlimab – increasing their chance of stabilizing or slowing the progression of their disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK